Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
A8MXD5
UPID:
GRCR1_HUMAN
Alternative names:
-
Alternative UPACC:
A8MXD5
Background:
Glutaredoxin domain-containing cysteine-rich protein 1, identified by the accession number A8MXD5, is implicated in the structural integrity of actin filaments within the stereocilia of sensory cells. This protein's role is pivotal in maintaining the architecture necessary for proper sensory function.
Therapeutic significance:
Linked to Deafness, autosomal recessive, 25, this protein's dysfunction manifests as moderate to severe hearing loss, with some cases showing progressive deterioration. Understanding the role of Glutaredoxin domain-containing cysteine-rich protein 1 could open doors to potential therapeutic strategies for sensorineural deafness, offering hope for improved treatment options.